TrialOncoimmunology2025

A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophages.

Katherine M Bever et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.